Lonza acquires Simbiosys Biowares' preclinical cell and molecular biology group

Saturday, 21 November, 2009 | Supplied by: Capsugel Australia Pty Ltd


Lonza has completed the acquisition of the preclinical cell and molecular biology assets of Simbiosys Biowares India, a biology outsourcing company, expanding its cell-biology platform.

Simbiosys’s cell and molecular biology group specialises in primary cell isolation and tissue sourcing and in performing preclinical services to mid-size pharmaceutical companies.

Simbiosys Biowares India offers preclinical services in the areas of: drug discovery services (includes lead validation and lead development using in-vitro and in-vivo ADME-Tox assays); molecular biology contract research services (including DNA amplification and cloning, DNA/RNA isolation, synthetic gene construction and quantitative PCR); biopharmaceutical services (includes process design optimisation of fermentation technology for producing small-molecules, proteins and mAbs for therapeutic, diagnostic and research applications).

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Amsbio Acepix FFPE tissue blocks

Amsbio has expanded its range of high-quality formalin-fixed, paraffin-embedded (FFPE) tissues...

Promega Paradyme 27GY STR System

The Paradyme 27GY STR System features a novel enzyme that reduces the most common type of...

Mercodia Insulin MBeads Assay

The assay is designed to offer high accuracy by specifically measuring human insulin while...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd